Syngene invests in capacity despite Q3 revenue pressures
after close1 source ↓written by the desknot a recommendation
- and is committed
- 2035
Syngene International faced revenue pressure in Q3 due to a significant biologics programme impacting margins. The company has extended its partnership with Bristol Myers Squibb to 2035 and is committed to capital expenditure for new facilities and technology platforms. This strategic focus aims to bolster long-term growth despite current challenges.
Not investment advice. For informational purposes only.